Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-10-03
2006-10-03
Smith, Lynette R.F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S009340, C424S130100, C424S139100, C424S150100, C424S178100, C424S184100, C424S185100, C424S234100, C424S237100, C424S243100, C424S278100, C435S069300, C436S086000, C530S300000, C930S010000, C930S200000
Reexamination Certificate
active
07115268
ABSTRACT:
This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates to peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, which may be polymeric, and carrier-conjugates thereof. The invention also relates to serum antibodies induced by the peptides and carrier-conjugates and their use to prevent, treat, or protect against the toxic effects of most, if not all, of the staphylococcal and streptococcal toxins.The invention also relates to diagnostic assays and kits to detect the presence of staphylococcal and streptococcal toxins, or antibodies thereto. The invention also relates isolated and purified to nucleic acids encoding the peptides of the invention and transformed host cells containing those nucleic acids.
REFERENCES:
patent: 5378607 (1995-01-01), Chelladurai et al.
patent: 5437978 (1995-08-01), Ubukata et al.
patent: 5470716 (1995-11-01), Leung et al.
patent: 5476767 (1995-12-01), Leung et al.
patent: 5519114 (1996-05-01), Johnson et al.
patent: 5529934 (1996-06-01), Chelladurai et al.
patent: 5545716 (1996-08-01), Johnson et al.
patent: 5585465 (1996-12-01), Leung et al.
patent: 5601830 (1997-02-01), Su et al.
patent: 5705151 (1998-01-01), Dow et al.
patent: 5728388 (1998-03-01), Terman
patent: 6075119 (2000-06-01), Bannan et al.
patent: WO 91/10680 (1991-07-01), None
patent: WO 93/24136 (1993-12-01), None
patent: WO 94/20124 (1994-09-01), None
patent: WO 94/25483 (1994-11-01), None
patent: WO 96/36366 (1996-11-01), None
patent: WO 96/40930 (1996-12-01), None
patent: WO 98/29444 (1998-07-01), None
patent: WO 98/45325 (1998-10-01), None
patent: WO 98/57657 (1998-12-01), None
Harris, T.O. and Betley, M.J., “Biological activities of Staphylococcal-enterotoxin type-A mutants with N-Terminal Substitutions,”Infect. Immun.63(6):2133-2140 (1995).
Hartwig, U.F.., et al., “Mutations affecting MHC class II binding of the superantigen streptococcal erythrogenic toxin A”,Intern'l Immunol., 5:869-75 (1993).
Hayball, J.D., et al. “The domain structure and functional relationships in the bacterial superantigen SEB, ”Biol. Chem. Hoppe-Seyler376:303-309 (1995).
Hoffmann, M.L., et al., “Predictions of T-Cell Receptor-and Major Histocompatibility Complex-Binding Sites on Staphylococcal Enterotoxin C1”,Infect. Immun., 62(8):3396-3407 (1994).
Hovde, C.J., et al. “Investigation of the role of disulphide bond activity and structure of staphylococcal enterotoxin C1,”Mol. Micro.13(5):897-909 (1994).
Huang, I.Y., et al., “Complete amino acid sequence of staphylococcal enterotoxin A”,J. Biol. Chem., 262(15) 7006-7013 (1987).
Huang, I.Y., et al., “The primary structure of staphylococcal enterotoxin B. III. The cyanogen bromide peptides of reduced and aminoethylated enterotoxin B, and the complete amino acid sequence”,J. Biol. Chem.245(14):3518-25 (1970).
Hynes, W.L., et al. “Immunologic Cross-Reactivity of Type A Streptococcal Exotoxin (Erythrogenic Toxin) and Staphylococcal Enterotoxins B and C1”,Infect. Immun., 55(3):837-838 (1987).
Iandolo, J.J., “Genetic analysis of extracellular toxins of Staphylococcus aureus”,Annu. Rev. Microbiol., 43:375-402 (1989).
Jett, M., et al., “Identification of Staphylococcal Enterotoxin B Sequences Important for Induction of Lymphocyte Proliferation by Using Synthetic Peptide Fragments of the Toxin”,Infect. Immun., 62(8):3408-3415 (1994).
Kline, J.B. and Collins, J.M., “Analysis of superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A,”Infect. Immun.64(3):861-869 (Mar. 1996).
International Search Report from related application PCT/US99/22180, international filing date: Sep. 24,1999; claimed priority date: Oct. 7, 1998.
Bannan, J. et al., “Structure and Function of Streptococcal and Staphylococcal Superantigens in Septic Shock”,Infectious Disease Clinics of North America, 13(2):387-396 (Jun. 1999); (mailed May 11, 1999 according to the publisher, W.B. Saunders Co.).
Fischetti, V.A. et al., “Streptococcal M Protein Extracted By Nonionic Detergent”,The Jounal of Experimental Medicine. 144/1:32-53 (1976).
Griggs, N.D. et al., “Mapping of Multiple Binding Domains of the Superantigen Staphylococcal Enterotoxin A for HLA”,J. Immunol., 148(8):2516-2521 (1992).
Huang, I.Y. et al., “Complete amino acid sequence of staphylococcal enterotoxin A”,J. Biol. Chem., 262(15):7006-7013 (1987).
Pontzer, C.H. et al., “Agonist Properties of a Microbial Superantigen Peptide”,Biochem. Biophy. Res. Comm., 193(3):1191-1197 (1993).
Reda, K.B. et al., “Molecular Characterization and Phylogenetic Distribution of the Streptococcal Superantigen Gene (ssa) fromStreptococcus pyogenes”,Infection and Immunity, 62/5:1867-1874 (May 1994).
Van Den Busshe, R.A., et al., “Molecular Evolution of the Staphylococcal and Streptococcal Pyrogenic Toxin Gene Family”,Molecular Phylogenetics and Evolution, 2:281-292 (1993).
Ren, K et al., “Characterization and Biological Properties of a New Staphylococcal Exotoxin”,J. Exp. Med.,180:1675-1683 (Nov. 1994).
Copy of Search Report in PCT/US98/06663 (listing references and related patents).
Bannan, J. et al., “Structure and Function of Streptococcal and Staphylococcal Superantigens in Septic Shock”,Infectious Disease Clinics of North America13(2):387-396 (Jun. 1999); (mailed May 11, 1999 according to the publisher, W.B. Saunders Co.).
Bannan, J.D. et al., “Neutralization Of Streptococcal Pyrogenic Exotoxins And Staphylococcal Enterotoxins by Antiserum To Synthetic Peptides Representing Conserved Amino Acid Motifs”,Adv. Exp. Med. Biol.418:903-907 (1997); (published May 1997 in U.S. and Sep. 1997 in britain according tot he publisher's (Plenum Press, New York) catalog at http://www.plenum.com/title.cgi?0306456036).
Bavari, S. et al., “Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A”,Journal of Infectious Diseases174(2):338-45 (1996).
Blomster-Hautamaa, E.A. et al. “Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromide-generated toxin fragments,”J. Immunol.137(11):3572-3576 (1986).
Bohach, G.A., et al., “Biological and immunological properties of the carboxyl terminus of Staphylococcal entero-toxin C1,”Infect. Immun.57(1):23-28 (1989).
Bonventre, P.F. et al., “A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity, ”Infect. Immun.63(2):509-515 (1995).
Chu, N.R. et al., “Comparison of peptide and superantigen-induced anergy in a peptide-specific polyclonal human T cell line,”Int. Immtunol.7(7):1057-1063 (1995).
Drynda, A., et al., “Role of a carboxy-terminal site of toxic shock syndrome toxin 1 in eliciting immune responses of human peripheral blood mononuclear cells,”Infect. Immun.63(3):1095-1101 (1995).
Edwin, C., et al., “Structure-activity relationship of toxic-shock-syndrome toxin-1:derivation and characterization of immunologically and biologically active fragments,”J. Infect. Dis.158(6):1287-1295 (1988).
Edwin,C., et al., “Specificity and cross-reactivity of staphylococcal enterotoxin A monoclonal antibodies with enterotoxins B,C1,D, and E”,Applied & Environmental Microbiology, 52(6): 1253-7 (1986).
Fischetti, V.A., et al., “Streptococcal M Protein Extracted By Nonionic Detergent”,The Journal of Experimental Medicine, 144/1:32-53 (1976).
Griggs, N.D.., et al “Mapping of Multiple Binding Domains of the Superantigen Staphylococcal Enterotoxin A for HLA”,J. Immunol., 148(8):2516-2521 (1992).
Grossman, D., et al., “Mu
Bannan Jason D.
Visvanathan Kumar
Zabriskie John B.
Cooper & Dunham LLP
Hines Ja'Na
Smith Lynette R.F.
The Rockefeller University
White, Esq. John P.
LandOfFree
Peptides useful for reducing symptoms of toxic shock... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides useful for reducing symptoms of toxic shock..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides useful for reducing symptoms of toxic shock... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3618056